Atai Life Sciences says Srinivas Rao assumes role of sole CEO

More on ATAI Life Sciences

• RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up
• Massachusetts psychedelics legalization initiative poised to fail

• Seeking Alpha | January 10, 2025

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments t

Yahoo | January 10, 2025

US Penny Stocks To Consider In December 2024

As the United States stock market navigates a period of volatility, with major indexes managing to hold onto gains despite recent fluctuations, investors are exploring diverse opportunities. Penny stocks, though often viewed as a throwback term, continue to offer potential for growth by representing smaller or newer companies at lower price points. When these stocks are backed by strong financials and solid fundamentals, they can provide an intriguing opportunity for investors seeking hidden...

Yahoo | December 30, 2024

Oxbridge Re Holdings Among 3 US Penny Stocks To Watch

The U.S. stock market has recently shown signs of recovery, with the S&P 500 and Nasdaq Composite rebounding after a challenging week, highlighting the resilience of equities amid fluctuating investor sentiment. Penny stocks may be an older term, but they continue to offer intriguing investment opportunities by allowing investors to access potential growth in smaller or newer companies at lower price points. When these stocks are supported by strong financial health and solid fundamentals,...

Yahoo | November 19, 2024

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24 - Remain on track to initiate a Phase 2 study of EMP-01 (oral R-MDMA) in social anxiety disorder patients around YE’24 - Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) --

Yahoo | November 13, 2024

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company’s finance and accounting functions, including SEC reporting and investor relations. “We are pleased to welcome Greg to Altimmune’s executive team during such a pivotal time in our evolution. He has a wealth of experience that we believ

Yahoo | November 11, 2024

374Water And 2 Other Promising US Penny Stocks To Watch

As the U.S. stock market experiences a pullback from record highs, with major indices like the Dow Jones and S&P 500 seeing declines, investors are closely watching economic indicators and corporate earnings reports for signs of future trends. In such a fluctuating environment, penny stocks—often representing smaller or newer companies—can present intriguing opportunities for those willing to look beyond established names. Despite being considered somewhat outdated as a term, these stocks...

Yahoo | October 21, 2024

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company’s Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company’s participation: Format: Virtual fireside chat Date: Wednesday

Yahoo | October 15, 2024

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and

Yahoo | September 4, 2024

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE’24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:

Yahoo | August 13, 2024